GSK (GLAXF) Ending Cash Position: $4,265 Mil (As of Mar. 2026)


GLAXF GSK PLC GLAXF
75 GF Score
Price $25.77
GF Value $21.79
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is GSK Ending Cash Position?

GSK GLAXF 75 Ending Cash Position is $4,265 Mil as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.79 (Modestly Overvalued). The stock has 3 warning signs investors should review.

GSK's Ending Cash Position for the quarter that ended in Mar. 2026 was $4,265 Mil.

GSK's quarterly Ending Cash Position increased from Sep. 2025 ($3,728 Mil) to Dec. 2025 ($4,293 Mil) but then declined from Dec. 2025 ($4,293 Mil) to Mar. 2026 ($4,265 Mil).

GSK's annual Ending Cash Position increased from Dec. 2023 ($3,618 Mil) to Dec. 2024 ($4,302 Mil) but then declined from Dec. 2024 ($4,302 Mil) to Dec. 2025 ($4,293 Mil).

GSK Ending Cash Position Related Terms

GSK Ending Cash Position Historical Data

* Premium members only.

The historical data trend for GSK's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Ending Cash Position Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,078.46 4,171.74 3,617.72 4,302.15 4,293.17

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,492.25 4,510.18 3,728.38 4,293.17 4,265.33
GLAXF
75GF Score
GSK PLC GLAXF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

GSK's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4555.557+-262.384
=4,293

GSK's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4333.333+-68
=4,265

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $4,265 Mil mean?
GSK (GLAXF) has a Ending Cash Position of $4,265 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on GSK and its competitors.
Is GSK's Ending Cash Position too high?
GSK's current Ending Cash Position is $4,265 Mil. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Ending Cash Position compare to LLY and JNJ?
GSK's Ending Cash Position of $4,265 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on GSK and its competitors. GSK's current Ending Cash Position is $4,265 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.79, compared to a current price of $25.77 — trading 18.3% above its estimated fair value. The current Ending Cash Position is $4,265 Mil. GSK's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For GSK (GLAXF), the current Ending Cash Position is $4,265 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $25.77 is trading 18.3% above its estimated GF Value™ of $21.79. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • Ending Cash Position: $4,265 Mil
  • GF Value™: $21.79 vs. price of $25.77 (18.3% above fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score

Get the complete analysis for GLAXF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.77
Price
$21.79
GF Value